XT
RANI icon

XTX Topco’s Rani Therapeutics RANI Stock Holding History

XTX Topco’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-44,077
Closed -$22K – 3701
2025
Q3 		$22K Buy
+44,077
New +$23K ﹤0.01% 2310
2025
Q2 		– Sell
-10,996
Closed -$13.9K – 3020
2025
Q1 		$13.9K Sell
10,996
-1,894
-15% -$2.8K ﹤0.01% 2204
2024
Q4 		$17.7K Buy
+12,890
New +$27.1K ﹤0.01% 2058

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

XTX Topco's RANI Position: Q4 2025 in Review

XTX Topco sold out of Rani Therapeutics (RANI) in Q4 2025, closing a stake of 44,077 shares — an estimated $22K sold.

XTX Topco first reported a position in RANI in Q4 2024 and held it in 3 quarters. The position peaked at $22K in Q3 2025. 64 funds tracked by Wall St. Rank hold RANI as of Q4 2025.

  • XTX Topco reported no remaining Rani Therapeutics position as of Q4 2025 after selling out during the quarter.
  • XTX Topco sold 44,077 Rani Therapeutics shares in Q4 2025, an estimated $22K.
  • XTX Topco first reported a position in Rani Therapeutics in Q4 2024 and held it in 3 quarters.
  • XTX Topco's Rani Therapeutics position peaked at $22K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.